LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
5.89
+0.10 (1.73%)
At close: Jul 2, 2026, 4:00 PM EDT
5.90
+0.01 (0.17%)
After-hours: Jul 2, 2026, 6:55 PM EDT

LENZ Therapeutics Stock Forecast

LENZ's stock price has decreased by -80.4% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 7 analysts polled by S&P Global, LENZ Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $32. The average 1-year stock price forecast is 443.29% higher than the current stock price, while the lowest is $12 (+103.74%) and the highest is $60 (+918.68%).

Price Target: $32 (+443.29%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$12$32$31$60
Change+103.74%+443.29%+426.32%+918.68%
* Price targets were last updated on May 13, 2026.

Analyst Ratings

The average analyst rating for LENZ Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy666666
Buy111100
Hold000011
Sell000000
Strong Sell000000
Total777777

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
William Blair
William Blair
Buy
Maintains
n/a
BuyMaintainsn/an/aJun 24, 2026
Citi
Citi
Buy
Reiterates
$26$20
BuyReiterates$26$20+239.56%May 13, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$29$31
BuyMaintains$29$31+426.32%May 12, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$48$38
BuyReiterates$48$38+545.16%May 12, 2026
Piper Sandler
Piper Sandler
Hold
Downgrades
$39$12
HoldDowngrades$39$12+103.74%May 12, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
19.03M
from 19.09M
Decreased by -0.29%
Revenue Next Year
64.52M
from 19.03M
Increased by 239.00%
EPS This Year
-4.56
from -2.85
EPS Next Year
-3.47
from -4.56
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-15.00M--19.09M19.03M
Revenue Growth
------0.29%
Operating Income
-6.69M-10.48M-72.43M-58.61M-91.14M-150.66M
Net Income
-7.56M-10.81M-69.97M-49.77M-82.13M-141.23M
EPS
-----2.85-4.56
Free Cash Flow
-99.13K-34.21M-40.65M-40.25M-207.50M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High24.8M
Avg19.0M
Low12.8M

Revenue Growth

Revenue Growth202620272028
High
30.2%
Avg
-0.3%
Low
-32.9%

EPS Forecast

EPS202620272028
High-3.55
Avg-4.56
Low-5.56

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-